Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Pantoprazole in Chronic Acid Peptic Complaints
NCT00261300Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2000
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pantoprazole in gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), sponsored by Takeda. Primary endpoint: Safety (adverse events, laboratory values) at 5 years. Started Oct 2000; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT00261300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261300.